A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

Gut

Volumn 56, Issue 12, 2007, Pages 1747-1753

  Omata, Masao ^a   Yoshida, Haruhiko ^a   Toyota, Joji ^b   Tomita, Eiichi ^c   Nishiguchi, Shuhei ^d   Hayashi, Norio ^e   Iino, Shiro ^f   Makino, Isao ^g   Okita, Kiwamu ^h   Toda, Gotaro ⁱ   Tanikawa, Kyuichi ^j   Kumada, Hiromitsu ^k  

^a UNIVERSITY OF TOKYO   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f Seizankai Kiyokawa Hospital   (Japan)

^g Hokushinkai Megumino Hospitals   (Japan)

^h Shimonoseki Kosei Hospital   (Japan)

ⁱ Senpo Tokyo Takanawa Hospital   (Japan)

^j Intl Institute for Liver Research   (Japan)

^k TORANOMON HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEPATITIS C; HUMAN; LONG TERM CARE; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; UPPER ABDOMINAL PAIN; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; VIRAL LOAD;

EID: 36749040213     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.120956     Document Type: Article

References (32)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
2. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
3. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(Suppl 1):8-17.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Fried MW, Shiftman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1:834-6.
7. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-74.
8. Leuschner U, Leuschner M, Sieratzki J, et al. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985;30:642-9.
9. Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994;20:558-64.
10. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
11. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
12. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
13. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999;29:1007-12.
14. Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
15. Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-18.
16. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
17. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-60.
18. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-31.
19. Osuga T, Tanaka N, Matsuzaki Y, et al. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sci 1989;34(12 Suppl):49S-51S.
20. Podda M, Ghezzi C, Battezzati PM, et al. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98:1044-50.
21. Kiso S, Kawata S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. J Gastroenterol 1996;31:75- 80.
22. Attili AF, Rusticali A, Varriale M, et al. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol 1994;20:315-20.
23. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
24. Nakamura K, Yoneda M, Takamoto S, et al. Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. J Gastroenterol Hepatol 1999;14:413-18.
25. Miura T, Ouchida R, Yoshikawa N, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001;276: 47371-8.
26. Ikegami T, Matsuzaki Y, Fukushima S, et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005;41:896-905.
27. Poynard T, Bedossa P, Opolon P, OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
28. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
29. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
30. Yoshida H, Shiratori Y, Moriyama M, et al. IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-81.
31. Tarao K, Rino Y, Ohkawa S, et al. Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A. Intervirology 2004;47:65-71.
32. Tarao K, Fujiyama S, Ohkawa S, et al. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol Biomarkers Prev 2005;14:164-9.